Bluejay Therapeutics, Inc. – 2025 Financial Results and Merger with Mirum Pharmaceuticals

Bluejay Therapeutics, Inc. has released its audited consolidated financial statements for the year ended December 31, 2025, offering a deep insight into the company’s financial position ahead of its merger with Mirum Pharmaceuticals, Inc. The report includes a comprehensive review of financial performance, liquidity status, significant transactions, and other key developments that could influence shareholder value. Below, we break down the most critical elements for investors and stakeholders.

Key Financial Highlights

• Net Loss: Bluejay reported a net loss of \$101.7 million for 2025, driven primarily by high research and development (R&D) expenses and general administrative costs.
• Operating Expenses: R&D expenses stood at \$87.1 million, while general and administrative expenses totaled \$17.6 million. Total operating expenses amounted to \$104.8 million.
• Cash Position: As of December 31, 2025, the company held \$19.998 million in cash and cash equivalents and \$56.061 million in short-term marketable securities, amounting to \$80.6 million in total current assets.
• Stockholders’ Deficit: The company reported a significant stockholders’ deficit of \$178.3 million due to accumulated operating losses.
• Comprehensive Loss: Including unrealized gains on marketable securities, the comprehensive loss for the year was \$101.4 million.

Liquidity Concerns and Going Concern Statement

• Bluejay’s auditors highlighted that the company’s existing cash resources were insufficient to fund operations for a full year beyond the financial statement issuance date. This raised substantial doubt about Bluejay’s ability to continue as a going concern.
• However, the company announced that Mirum Pharmaceuticals, its soon-to-be parent, had committed to providing sufficient funding post-merger, alleviating these concerns and ensuring operational continuity.

Merger with Mirum Pharmaceuticals – Price-Sensitive Event

• Merger Completion: On January 23, 2026, Bluejay completed its merger with Mirum Pharmaceuticals, becoming a wholly owned subsidiary. This strategic transaction is a major development with significant implications for Bluejay’s future operations and shareholder value.
• Transaction Costs: Bluejay expects to incur approximately \$24 million in merger-related costs, the majority (\$22 million) related to advisory and professional services, and \$2 million for severance payments to employees whose employment will terminate as a result of the merger.
• Contingent Payments: A key highlight is the \$4 million Business Milestone Payment due to Novartis Pharma AG as a result of the merger, as per a pre-existing license agreement. This contingent consideration was previously recognized as a derivative liability and became payable upon the completion of the merger.

Major Licensing and Asset Transactions

• Novartis License Agreement: Bluejay holds an exclusive global license from Novartis for key hepatitis programs, entailing milestone and royalty payments. In 2025, Bluejay met two development milestones, resulting in \$4 million in milestone payments to Novartis. The merger also triggered an additional \$4 million payment to Novartis.
• Lonza License Agreement: Bluejay secured rights to Lonza’s cell line technology for the manufacture of its lead product, brelovitug, with contingent license fees and royalties depending on future manufacturing arrangements and commercialization.
• Flashpoint License Agreement: In January 2024, Bluejay obtained exclusive global rights to certain Exicure, Inc. patents for hepatitis therapies, for an upfront payment of \$0.5 million. The license was later assigned to Flashpoint Therapeutics at no additional cost.
• Asset Sale to Madrigal Pharmaceuticals: On January 21, 2026, Bluejay sold all rights to the compound BJT-188 and related assets to Madrigal Pharmaceuticals for \$6 million in cash.

Product Pipeline and Research Focus

• The company’s leading asset is brelovitug (BJT-778), a monotherapy candidate for chronic hepatitis delta, recognized as the most severe form of viral hepatitis.
• Bluejay, with a U.S. headquarters and an Australian subsidiary, is in the clinical development stage and has not generated revenue from product sales.

Capital Structure and Shareholder Information

• Preferred Stock: As of year-end, Bluejay had 43,058,860 shares of redeemable convertible preferred stock outstanding, with an aggregate liquidation preference of \$243 million.
• Convertible Preferred and Common Stock: The company also had 1,146,656 shares of convertible preferred stock and 7,743,856 shares of common stock outstanding.
• Stock Option Plan: The 2021 Stock Incentive Plan authorized issuance of over 8.3 million shares for employees and directors, with 5.7 million options outstanding as of December 31, 2025.
• Valuation Allowance: Bluejay recorded a full valuation allowance against its U.S. deferred tax assets due to a history of operating losses and uncertainty regarding future profitability.

Other Material Disclosures

• No Legal Proceedings: As of the end of 2025, the company was not involved in any litigation or legal actions that could materially affect its financial position.
• Leases and Commitments: The company’s primary facility lease in Redwood City, CA, runs through 2027 with a current annual rent obligation of approximately \$0.6 million.
• R&D Tax Incentives: The Australian subsidiary is eligible for significant R&D tax refunds, with \$1.3 million recorded as receivable in 2025.

Accounting Changes and New Standards

• Bluejay adopted several new FASB accounting standards in 2025, including updated income tax disclosure requirements. Additional new standards on expense disaggregation, business combinations, derivatives, and government grants will be effective in future years, with the company currently evaluating their impact.

Shareholder Takeaways and Potential Price-Sensitive Issues

• The completion of the merger with Mirum Pharmaceuticals is the most significant, price-sensitive event, ensuring Bluejay’s financial stability and opening new strategic opportunities.
• Large merger-related transaction costs and the triggering of the \$4 million Novartis milestone payment are material outflows that investors should factor into their valuation models.
• The sale of non-core assets (BJT-188) for \$6 million and ongoing licensing deals reflect active portfolio management and capital recycling.
• Ongoing R&D spending and lack of current revenue reinforce Bluejay’s profile as a high-risk, high-reward biotech dependent on future clinical and regulatory milestones.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors are urged to conduct their own due diligence and consult with financial advisors before making investment decisions. The information presented here is based on publicly available filings and may not include all relevant developments or risks.

View Mirum Pharmaceuticals, Inc. Historical chart here